This disclosure relates generally to prosthetic valves and delivery systems for prosthetic valves. More specifically, this disclosure relates to prosthetic heart valves and methods thereof.
The native heart valves (the tricuspid valve, pulmonary valve, mitral valve, and aortic valve) play an important role in regulating flow of blood through the cardiovascular system. However, the native heart valves may become damaged or impaired due to, for example, cardiovascular diseases, infections, or congenital malformations, thus limiting the ability of the native heart valves to regulate blood flow. This deficiency may result in reduced cardiovascular function or even death.
To treat these conditions, prosthetic heart valves may be implanted at or near the site of a damaged or impaired native valve. A prosthetic heart valve may assist or replace the functionality of an impaired native valve, leading to better regulation of blood flow and improved cardiovascular function. However, many existing prosthetic heart valves require implantation via an open heart procedure, which is highly-invasive and may cause life-threatening complications. Other prosthetic valves may be collapsed within a prosthetic valve delivery system and advanced into the heart, at which point the prosthetic valve may be removed from the delivery system and expanded at the native valve site. However, many of these prosthetic valves are large in size and therefore difficult to deliver into the heart without causing damage to healthy tissue along the implantation route. In addition, once these prosthetic valves are situated within the heart, they may be difficult to securely implant at the native valve site due to their complex structure and the limited maneuverability of existing prosthetic valve delivery systems within the heart. Moreover, many prosthetic valves are so large that they may protrude several centimeters into surrounding heart chambers once they are implanted, impairing cardiac filling and causing injury to the anatomy within the heart.
Thus, there remains a need for prosthetic heart valves that are smaller in size but that are still configured to assist or replace the functionality of a diseased or damaged native heart valve. In addition, there remains a need for prosthetic heart valves that are more easily maneuvered into the heart and securely implanted at the site of a native heart valve. Moreover, there remains a need for improved prosthetic heart valve delivery systems that are configured to securely implant a prosthetic heart valve at an implantation site. The present disclosure provides prosthetic heart valves with a reduced axial length such that the prosthetic heart valves may be more easily delivered into the heart and may exhibit less protrusion into the chambers of the heart. The present disclosure also provides improved prosthetic heart valve delivery systems and methods of implanting prosthetic heart valves, such that prosthetic heart valves may be securely anchored at the implantation site.
The present disclosure discloses prosthetic valves for implantation within a native mitral valve and methods for implanting prosthetic valves within a native mitral valve. Particular examples of the disclosure may pertain to a prosthetic valve formed at least partially of a valve body, a plurality of tissue anchors arranged about the valve body, and a protective fabric covering.
According to an exemplary embodiment of the present disclosure, a prosthetic valve for implantation within a native mitral valve is provided. The prosthetic valve includes an annular valve body. The prosthetic valve additionally includes a plurality of tissue anchors arranged about the valve body and configured to extend from connection points on the valve body. The prosthetic valve additionally includes at least one protective fabric covering extending over each of the connection points between each tissue anchor and the valve body.
Each connection point is covered by a separate protective fabric covering. Each of the at least one protective fabric covering covers less than half of a surface area of the corresponding tissue anchor. Each of the at least one protective fabric covering is arranged to expose a terminal end of the corresponding tissue anchor. The at least one protective fabric covering is at least partially constructed of PET. Stitching passes through the at least one protective fabric covering to secure the at least one protective fabric covering relative to the annular valve body. Stitching is configured to secure distinct portions of the at least one protective fabric covering together. Stitching is additionally configured to secure a portion of the at least one protective fabric covering to a skirt layer positioned beneath the at least one protective fabric covering. The at least one protective fabric covering is positioned over a liner which covers a majority of a surface area of one or more of the tissue anchors. At least two of the connection points are covered by separate protective fabric coverings that are substantially aligned in a common plane. The separate protective fabric coverings are substantially aligned in a common lateral plane. The at least one protective fabric covering is positioned in a radially outer direction relative to the annular valve body. The plurality of tissue anchors are configured to expand from a radially-contracted configuration to a radially-expanded configuration. The at least one protective fabric covering is arranged so that the at least one protective fabric covering does not impede movement of the plurality of tissue anchors from the radially-contracted configuration to the radially-expanded configuration. The at least one protective fabric covering includes a single strip of fabric wrapped about the at least one connection point. A terminal end of at least one tissue anchor is configured to be situated in an atrial direction relative to the at least one protective fabric covering. The prosthetic valve additionally includes a plurality of leaflets situated within the annular valve body. A point of connection of the plurality of leaflets to the annular valve body is situated in a ventricular direction relative to the at least one protective fabric covering. The tissue anchors are configured to engage ventricular tissue of a native heart valve. The prosthetic valve additionally includes a plurality of atrial tissue anchors configured to engage atrial tissue of the native heart valve. The annular valve body includes an annular outer frame and an inner frame situated at least partially within the annular outer frame. The ventricular tissue anchors extend from the annular outer frame and the atrial tissue anchors extend from the inner frame. The at least one protective fabric covering is positioned in a radially outer direction relative to the annular outer frame and relative to the inner frame. The at least one protective fabric covering is situated in a ventricular direction relative to the atrial tissue anchors. The at least one protective fabric covering is angularly offset from the atrial tissue anchors.
Additional features and advantages of the disclosed embodiments will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the disclosed embodiments. The features and advantages of the disclosed embodiments will be realized and attained by the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are examples and explanatory only and are not restrictive of the disclosed embodiments as claimed.
The accompanying drawings constitute a part of this specification. The drawings illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the disclosed embodiments as set forth in the accompanying claims.
Exemplary embodiments are described with reference to the accompanying drawings. In the figures, which are not necessarily drawn to scale, the left-most digit(s) of a reference number identifies the figure in which the reference number first appears. Wherever convenient, the same reference numbers are used throughout the drawings to refer to the same or like parts. While examples and features of disclosed principles are described herein, modifications, adaptations, and other implementations are possible without departing from the spirit and scope of the disclosed embodiments. Also, the words “comprising,” “having,” “containing,” and “including,” and other similar forms are intended to be equivalent in meaning and be open ended in that an item or items following any one of these words is not meant to be an exhaustive listing of such item or items, or meant to be limited to only the listed item or items. It should also be noted that as used in the present disclosure and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
In some embodiments of the present disclosure, an “atrial direction” may refer to a direction extending towards an atrium of the heart. For example, from a location within the left ventricle or the mitral valve, an atrial direction may refer to a direction extending towards the left atrium. Additionally, from a location within an atrium (e.g., the left atrium), an atrial direction may refer to a direction extending away from an adjacent atrioventricular valve (e.g., the mitral valve) and further into the atrium. For example, in
In some exemplary embodiments of the present disclosure, a “ventricular direction” may refer to a direction extending towards a ventricle of the heart. From a location within the left atrium or the mitral valve, a ventricular direction may refer to a direction extending towards the left ventricle. Additionally, from a location within a ventricle (e.g., the left ventricle), a ventricular direction may refer to a direction extending away from an adjacent atrioventricular valve (e.g., the mitral valve) and further into the ventricle. For example, in
Exemplary embodiments generally relate to prosthetic valves for implantation within a native valve and methods for implanting prosthetic valves within a native valve. In addition, exemplary embodiments generally relate to systems and methods for implantation of prosthetic valves by prosthetic valve delivery systems. While the present disclosure provides examples relating to prosthetic heart valves, and in particular prosthetic mitral valves, as well as delivery systems for prosthetic heart valves, it should be noted that aspects of the disclosure in their broadest sense are not limited to a prosthetic heart valve. Rather, the foregoing principles may be applied to other prosthetic valves as well. In various embodiments in accordance with the present disclosure, the term prosthetic valve refers generally to an implantable valve configured to restore and/or replace the functionality of a native valve, such as a diseased or otherwise impaired native heart valve.
An exemplary prosthetic valve may include a prosthetic valve configured to render a native valve structure non-functional, and may thus replace the function of the native valve. For example, an exemplary prosthetic valve may have a size and shape similar to the valve being replaced and may include a number of leaflet-like structures to regulate fluid flow and prevent backflow of blood through the valve. Additionally, or alternatively, an exemplary prosthetic valve may also include a prosthetic valve configured to leave the native valve structure intact and functional. An exemplary prosthetic valve may include a mitral valve, tricuspid valve, aortic valve, or pulmonary valve, as well as a valve outside of the heart, such as a venous valve, lymph node valve, ileocecal valve, or any other structure configured to control and/or regulate fluid flow in the body. An exemplary prosthetic valve may additionally or alternatively be configured to replace a failed bioprosthesis, such as a failed heart valve prosthesis.
Annular outer frame 1200 may include an outer frame tubular portion 1220, which may be formed of a plurality of struts intersecting at junctions to form a wire mesh, stent-like, or cage-like structure of the outer frame tubular portion 1220. Annular outer frame 1200 may also include at least one ventricular anchoring leg 1240, which may be configured to extend radially outward from the outer frame tubular portion and which may contact, or otherwise engage, tissue within or near the native valve to anchor the prosthetic valve within the native valve. In some embodiments, exemplary valve frame 1000 may include twelve ventricular anchoring legs 1240, which may be configured to engage ventricular tissue of a native atrioventricular valve.
Inner frame 1400 may include an inner frame tubular portion 1420, which may be formed of a plurality of struts intersecting at junctions to form a wire mesh, stent-like, or cage-like structure of the inner frame tubular portion 1420. Inner frame 1400 may also include at least one atrial anchoring arm 1440, which may be configured to extend radially outward from the inner frame tubular portion and which may contact, or otherwise engage, tissue within or near the native valve to anchor the prosthetic valve within the native valve. In some embodiments, exemplary valve frame 1000 may include twelve atrial anchoring arms 1440, which may be configured to engage atrial tissue of a native atrioventricular valve.
Outer frame tubular portion 1220 and inner frame tubular portion 1420 may together form an annular valve body 1020 of the prosthetic valve, which may have at least one opening and from which the ventricular anchoring legs 1240 and atrial anchoring arms 1440 may extend. Annular valve body 1020 may include an axial lumen 1022 extending through the annular valve body 1020 along a longitudinal axis 1800 of the prosthetic valve. In some embodiments, annular valve body 1020 may be configured to receive a flow control device, such as one or more prosthetic leaflets, within axial lumen 1022. Optionally, annular valve body 1020 may include one or more atrial end delivery posts 1027 along an atrial end (i.e., top end) of the annular valve body and/or one or more ventricular end delivery posts 1028 along a ventricular end (i.e., bottom end) of the annular valve body. Delivery posts 1027 and 1028 may be configured to removably engage a delivery device of the prosthetic valve, for example, to assist with placement of frame 1000 within or near a native valve.
Annular outer frame 2200 may include an outer frame tubular portion 3605, which may be formed of a plurality of struts intersecting at junctions to form a wire mesh, stent-like, or cage-like structure of the outer frame tubular portion 3605. For example, as illustrated in
Inner frame 2400 may include an inner frame tubular portion 3005, which may be formed of a plurality of struts intersecting at junctions to form a wire mesh, stent-like, or cage-like structure of the inner frame tubular portion 3005. For example, as illustrated in
Outer frame tubular portion 3605 and inner frame tubular portion 3005 may together form an annular valve body 2020 of the prosthetic valve, which may have at least one opening and from which the ventricular anchoring legs 2240 and atrial anchoring arms 2440 may extend. Annular valve body 2020 may include an axial lumen 2022 extending through the annular valve body 2020 along a longitudinal axis 2800 of the prosthetic valve. Annular valve body 2020 may have an atrial end 2024, a ventricular end 2025 opposite the atrial end, and an intermediate portion 2026 extending between the atrial and ventricular ends. In some embodiments, the atrial end may refer to the portion of the annular valve body configured to be situated at a location within the atrium that is furthest from an adjacent ventricle, when the prosthetic valve is implanted in a native valve. Similarly, the ventricular end may refer to the portion of the annular valve body configured to be situated at a location within the ventricle that is furthest from an adjacent atrim, when the prosthetic valve is implanted in a native valve. The intermediate portion 2026 may extend between the atrial end 2024 and ventricular end 2025. In some embodiments, annular valve body 2020 may include one or more ventricular end delivery posts 1028 along the ventricular end 2025 of the annular valve body. Axial lumen 2022 may include an inlet opening 2032 at the atrial end of the annular valve body, as well as an outlet opening 2036 at the ventricular end of the annular valve body.
In some embodiments, prosthetic valve 6000 may additionally include a protective sleeve 6102 wrapped around the rim 6800 of the ventricular outlet opening of annular valve body 2020; protective sleeve 6102 may be secured to annular valve body 2020 by stitching 6108. Additionally, or alternatively, prosthetic valve 6000 may include at least one liner 6310 extending around an external surface of the ventricular anchoring legs 2240, with at least one protective layer 6330 positioned around the distal leg ends 2244 and at least one protective covering 6320 wrapped around the proximal leg ends 3622. In some embodiments, the at least one protective covering 6320 may be secured to the skirt layer 6100 via stitching 6322.
Control handle assembly 7100 may include an outer sheath control handle 7120 having a steering knob 7122 configured to steer an outer sheath 7210 of the telescoping catheter assembly 7200. Control handle assembly 7100 may also include a guide catheter control handle 7140 having a steering knob 7142 configured to steer a guide catheter 7220 of the telescoping catheter assembly 7200.
Control handle assembly 7100 may also include an implant catheter control handle 7160 having a steering knob 7168 configured to steer an implant catheter 8100 of the telescoping catheter assembly 7200. Implant catheter control handle 7160 may also include a proximal capsule portion slider 7162, a distal capsule portion knob 7170, and a distal capsule portion knob lock 7172 configured to control release of the prosthetic valve 6000 from within delivery capsule 7300. Implant catheter control handle 7160 may also include a slide lock 7166 configured to lock the implant catheter control handle 7160 at a position within track 7420 of stand 7400.
Control handle assembly 7100 may also include a cradle 7180, which may be secured to stand 7400 via a locking mechanism that can be released by actuated of release button 7184. Cradle 7180 may include a rotation knob 7182 configured to control rotation of the outer sheath 7210 and guide catheter 7220. Cradle 7180 may also include a rotation knob 7186 configured to control rotation of the implant catheter 8100. Cradle 7180 may also include a knob 7188 configured to control relative axial movement between outer sheath control handle 7120 (which may be secured to outer sheath 7210) and guide catheter control handle 7140 (which may be secured to guide catheter 7220).
In the embodiment illustrated in
In
In
Various embodiments of the present disclosure relate to prosthetic valves, including prosthetic heart valves. While the present disclosure provides examples of prosthetic heart valves, and in particular prosthetic mitral valves, it should be noted that aspects of the disclosure in their broadest sense are not limited to a prosthetic mitral valve. Rather, the foregoing principles may be applied to other prosthetic valves as well. Prosthetic heart valve 6000, illustrated in
In some embodiments, a prosthetic valve may be configured for implantation at a treatment site within the body, such as within or adjacent to a native valve structure, such as a native mitral valve. In some embodiments, a prosthetic valve may be configured for transcatheter delivery to the implantation site via a variety of approaches, such as transapically, transatrially, and/or transseptally. In some embodiments, the prosthetic valve may be configured for implantation in the annulus or orifice of a native valve structure (e.g., a native mitral valve). For example, in
In some embodiments, an exemplary prosthetic valve may be configured for implantation within a native atrioventricular valve and may regulate blood flow between the atrium and ventricle. For example, prosthetic heart valve 6000 illustrated in
In some embodiments, the prosthetic valve may include an annular valve body. The exemplary annular valve body may be configured to receive or otherwise support a flow control device, such as one or more leaflets, for regulating flow of blood or other bodily fluids through the prosthetic valve. For example, the flow control device (e.g., leaflets) may be secured directly to the valve body and/or to an additional structure that is in turn secured to the valve body. As a result, when the prosthetic valve is implanted within a native valve (e.g., a mitral valve), the flow control device may regulate fluid passage through the native valve, thus restoring and/or replacing the functionality of the native valve. In some embodiments, the exemplary valve body may be annular or ring-shaped and may thus have at least one opening therein. In some embodiments, the at least one opening may extend longitudinally along the entire length of the annular valve body. For example,
The annular valve body may have a circular, oval-shaped, elliptical, or D-shaped cross-section and may be symmetrical about at least one axis thereof. Alternatively, the annular valve body may have any suitable cross-sectional shape with at least one opening therein. In some embodiments, at least a portion of the annular valve body may be cylindrical, with a substantially constant diameter along the entire longitudinal length thereof. Alternatively, the annular valve body may have a variable diameter at different portions thereof (e.g., at different longitudinal portions thereof). Advantageously, such a configuration may improve the seating of the annular valve body within the mitral valve orifice, providing an improved pressure fit therebetween.
In some embodiments, the annular valve body may be expandable, such as between a radially-contracted configuration (e.g., a crimped state) and a radially-expanded configuration. The diameter of the annular valve body may be reduced when the annular valve body assumes the radially-contracted configuration; for example, the annular valve body may be arranged in the radially-contracted configuration when the exemplary prosthetic valve is delivered to the implantation site. Conversely, the diameter of the annular valve body may be increased when the annular valve body assumes the radially-expanded configuration. For example, the annular valve body may expand to its largest possible diameter when it is in the radially-expanded configuration.
In some embodiments, the annular valve body may be configured for self-expansion to the radially-expanded configuration; that is, the valve body may be biased to assume the radially-expanded configuration due to, at least in part, the design and/or material composition of the annular valve body. Additionally, or alternatively, the annular valve body may be configured to expand due to application of radially expansive forces thereupon.
In some embodiments, the annular valve body may include a plurality of supporting members or struts. In some embodiments, the struts may intersect at junctions to form a wire mesh, stent-like, or cage-like structure of the annular valve body. In some embodiments, the struts of the annular valve body may be made of metals or alloys such as Nitinol.
In some embodiments, the annular valve body may include an atrial end. In some embodiments, the atrial end may refer to a portion of the annular valve body configured to be situated closest to an atrium of the heart when the annular valve body is positioned outside of the atrium. Additionally, or alternatively, the atrial end may refer to a portion of the annular valve body configured to be situated at a location within the atrium that is furthest from an adjacent ventricle. For example, as depicted in
In some embodiments, the annular valve body may include a ventricular end. In some embodiments, the ventricular end may refer to a portion of the annular valve body configured to be situated closest to a ventricle of the heart when the annular valve body is positioned outside of the ventricle. Additionally, or alternatively, the ventricular end may refer to a portion of the annular valve body configured to be situated at a location within the ventricle that is furthest from an adjacent atrium. For example, in some embodiments and as depicted in
In some embodiments, the annular valve body may include an intermediate portion extending between the atrial end and ventricular end of the annular valve body. In some embodiments, the intermediate portion of the annular valve body may constitute every portion of the annular valve body situated in between the atrial end and ventricular end of the annular valve body. For example, as depicted in
In some embodiments, the exemplary prosthetic valve may include one or a plurality of tissue anchors. In some embodiments, the tissue anchors may be configured to anchor the prosthetic valve at the implantation site, such as within or near the native mitral valve. In some embodiments, the tissue anchors may be configured to engage ventricular tissue of the native mitral valve to anchor the prosthetic valve therein. In some embodiments, the tissue anchors may be configured to be positioned at least partially within a ventricle upon implantation of the prosthetic valve, and to engage ventricular tissue of the native mitral valve. For example,
In some embodiments, the tissue anchors may be configured to minimize or prevent migration of the prosthetic valve, including in an atrial direction (that is, towards the atrium), after the prosthetic valve is implanted. This may be due, at least in part, to the engagement of the tissue anchors with native tissue (e.g., the ventricular side of the native mitral valve) and the inability of the tissue anchors to pass through the mitral valve orifice after the prosthetic valve is implanted. For example, the tissue anchors may have sufficient length such that they may be configured to have a greater radius than the native mitral valve. Additionally, or alternatively, the tissue anchors may be configured to grasp or clamp tissue of the native mitral valve to further anchor the prosthetic valve in place. For example, in the embodiment of
The prosthetic valve may include two tissue anchors, three tissue anchors, four tissue anchors, five tissue anchors, six tissue anchors, seven tissue anchors, eight tissue anchors, nine tissue anchors, ten tissue anchors, eleven tissue anchors, twelve tissue anchors, thirteen tissue anchors, fourteen tissue anchors, fifteen tissue anchors, sixteen tissue anchors, seventeen tissue anchors, eighteen tissue anchors, nineteen tissue anchors, twenty tissue anchors, or any other suitable number of tissue anchors. For example, exemplary prosthetic valve 6000 depicted in
In some embodiments, the tissue anchors may be arranged about the annular valve body. The tissue anchors may be arranged at a regular interval about the annular valve body; alternatively, the tissue anchors may be arranged at some other interval about the annular valve body. In some embodiments, the tissue anchors may be arranged about a circumference of the annular valve body such that the tissue anchors may be evenly aligned within a plane perpendicular to longitudinal axis 2800; that is, the tissue anchors, or certain portions thereof, may be situated at the same axial position along longitudinal axis 2800. For example, in
In some embodiments, the tissue anchors may be configured to extend from connection points on the annular valve body. In some embodiments, the connection points may refer to specific portions of the annular valve body to which the tissue anchors are connected to or otherwise secured. For example, in
In some embodiments, the exemplary prosthetic valve may include at least one protective fabric covering extending over each of the connection points between each tissue anchor and the valve body. The at least one protective fabric covering may refer to a particular material layer or textile configured to cover and protect at least a portion of the exemplary prosthetic valve. In some embodiments, the at least one protective fabric covering may be wrapped around at least a portion of the tissue anchors, including the connection points between the tissue anchors and the annular valve body, such that the connection points may be completely covered by the at least one protective fabric covering. For example,
Advantageously, the at least one protective fabric covering may protect the connection points between the tissue anchors and annular valve body during and after the implantation process of the prosthetic valve. The at least one protective fabric covering may also protect native tissue from being injured by the connection point. For example, the protective fabric covering may protect tissue from injury resulting from being pinched between a tissue anchor and the annular valve body, both of which may be constructed of a rigid material such as Nitinol. The protective fabric covering may also protect tissue within the ventricle, including the chordae tendineae, from rubbing against and being injured by the connection point.
In some embodiments, each connection point between the tissue anchors and the annular valve body may be covered by a separate protective fabric covering. In some embodiments, the prosthetic valve may include the same number of protective fabric coverings as tissue anchors. Alternatively, the prosthetic valve may include a greater number of protective fabric coverings than tissue anchors. For example, prosthetic heart valve 6000 depicted in
In some embodiments, each of the at least one protective fabric coverings may cover less than half of a surface area of the corresponding tissue anchor. As used herein, the expression “surface area” may refer to the portions of the tissue anchors on the outer surface of the tissue anchors. As discussed above, the protective fabric coverings may extend around at least a portion of the tissue anchors (e.g., the protective fabric coverings may be wrapped around the tissue anchors). As a result, the surface area of the tissue anchors may be at least partially covered by the protective fabric coverings. However, each of the at least one protective fabric coverings may be configured to extend around the tissue anchors such that less than half of the surface area of each tissue anchor is covered by the protective fabric coverings. In some embodiments, each of the at least one protective fabric coverings may cover less than a quarter of the surface area of the corresponding tissue anchor. Alternatively, each of the at least one protective fabric coverings may cover less than a tenth of the surface area of the corresponding tissue anchor. Without limitation, for example, each of the at least one protective fabric coverings may cover less than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 48%, 48.5%, 49%, 49.5%, or any other suitable portion of the corresponding tissue anchor.
In some embodiments, each of the at least one protective fabric covering may be arranged so as to expose a terminal end of the corresponding tissue anchor. That is, the protective fabric coverings may be arranged about the tissue anchors such that the distal, terminal ends of the tissue anchors are not covered by the protective fabric coverings. In some embodiments, the terminal ends of the tissue anchors may refer to the ends of the tissue anchors which are furthest from or most distal to the points of connection of the tissue anchors to the annular valve body. For example,
In some embodiments, the at least one protective fabric covering may be at least partially constructed of a polymer such as polyethylene terephthalate (PET). In some embodiments, the entirety of at least one protective fabric covering may be constructed of PET. In some embodiments, at least one protective fabric covering may be at least partially constructed of a synthetic organic material, a synthetic polymer, a natural polymer, and/or a thermoplastic polymer such as a polycarbonate, a polyoxymethylene, an acrylic, a nylon, a polyethylene, a tetrafluoroethylene, a polypropylene, a polystyrene, a polyvinyl chloride, or a fluoropolymer.
In some embodiments, the at least one protective fabric covering may be secured relative to the annular valve body, at least in part, by stitching. In some embodiments, an additional securing mechanism, such as an adhesive, staples, rivets, or other suitable fasteners may be used in combination with stitching to secure the protective fabric coverings relative to the annular valve body. In some embodiments, portions of the protective fabric coverings may be stitched directly to the annular valve body. Additionally, or alternatively, portions of the protective fabric coverings may be stitched to an intermediate structure, such as a protective liner, which may in turn be secured to the annular valve body. In some embodiments, the stitching may pass through the protective fabric coverings to secure the coverings relative to the annular valve body. For example, in
In some embodiments, the stitching passing through the at least one protective fabric covering to secure the at least one protective fabric covering relative to the annular valve body may be configured to secure distinct portions of at least one protective fabric covering together. That is, for at least one protective fabric covering, separate portions of the covering may be secured together by the stitching. In some embodiments, at least one protective fabric covering may have an elongated structure (e.g., a rectangular structure) extending between two opposite ends of the protective fabric covering; the two opposite ends of the elongated structure may be secured together by the stitching. For example, protective coverings 6320 depicted in
In some embodiments, the prosthetic valve may include a skirt layer extending around at least a portion of the annular valve body. The skirt layer may cover the outer surface of at least a portion of the annular valve body; additionally, or alternatively, the skirt layer may cover the interior surface of at least a portion of the annular valve body. For example, as mentioned above, prosthetic valve 6000 illustrated in
The skirt layer may cover the ventricular end of the annular valve body and may extend along a portion of the axial length of the annular valve body. The skirt layer may be secured relative to the ventricular end of the annular valve body, such as by stitching, adhesive, staples, rivets, and/or any suitable fasteners. For example, as illustrated in
The skirt layer may be connected to the annular valve body, for example, by stitching, adhesive, staples, rivets, and/or any suitable fasteners. In some embodiments, the skirt layer may be at least partially constructed of a fabric that is impermeable to blood but which may be configured to allow for tissue ingrowth. For example, the skirt layer may be constructed of at least one synthetic material, such as polyester material or a biocompatible polymer. Examples of a polyester material may include polyethylene terephthalate (PET) and expanded polytetrafluoroethylene (ePTFE), either alone, or in combination with at least one additional material. In some alternative embodiments, the skirt layer may be at least partially constructed of a biological material, such as pericardial tissue (e.g., bovine, porcine, or equine pericardium) or other biological tissue.
The skirt layer may be positioned beneath the at least one protective fabric covering; that is, the protective fabric covering may be situated over the skirt layer. In some embodiments, the stitching passing through the at least one protective fabric covering to secure the at least one protective fabric covering relative to the annular valve body may secure at least a portion of the at least one protective fabric covering to the skirt layer. For example, the stitching may pass through the protective fabric covering and portions of the skirt layer situated beneath and/or immediately adjacent to the protective fabric covering, thus securing the protective fabric covering and skirt layer together. For example, in
In some embodiments, the exemplary prosthetic valve may include a liner configured to cover a majority of a surface area of one or more of the tissue anchors. In some embodiments, a majority of a surface area of one or more of the tissue anchors may refer to more than half of the surface area of the one or more tissue anchors. Without limitation, for example, the liner may be configured to cover at least 51%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or any other suitable portion of the surface area of the one or more the tissue anchors. In some embodiments, the liner may be configured to cover the entire surface area of one or more of the tissue anchors. In some embodiments, each tissue anchor may be at least partially covered by a separate liner. Alternatively, one liner may cover the majority of a surface area of at least two tissue anchors. For example, in
In some embodiments, the at least one protective fabric covering may be positioned, at least partially, over the liner covering the tissue anchors. For example, as illustrated in
In some exemplary embodiments, at least two of the connection points between the tissue anchors and the annular valve body may be covered by separate protective fabric coverings. For example, all of the connection points between the tissue anchors and the annular valve body may be covered by separate protective fabric coverings. In such embodiments, the separate protective fabric coverings may be substantially aligned in a common plane. That is, the protective fabric coverings may be arranged within a common planar surface. For example, the separate protective fabric coverings may be substantially aligned in a common lateral plane. That is, the protective fabric coverings may be arranged within a plane substantially perpendicular to a longitudinal axis of the prosthetic valve. As a result, the protective fabric coverings may be configured at a common axial position along the longitudinal axis. For example, in
In some embodiments, at least one protective fabric covering may be positioned in a radially outer direction relative to the annular valve body. That is, the at least one protective fabric covering may be positioned exterior to the annular valve body, and at a greater distance from the longitudinal axis of the prosthetic valve than is the annular valve body. In some embodiments, the entirety of the at least one protective fabric covering may be positioned in a radially outer direction relative to the annular valve body. Alternatively, a portion of the at least one protective fabric covering may be positioned in a radially outer direction relative to the annular valve body. This may be achieved, for example, because the at least one protective fabric covering may be arranged along an exterior surface of the annular valve body. Alternatively, the at least one protective fabric covering may be positioned on an element (e.g., a tissue anchor) which may extend radially outwards from the annular valve body, thus positioning the at least one protective fabric covering in a radially outward direction from the annular valve body. For example, in
In some embodiments, the plurality of tissue anchors may be configured to expand between a radially-contracted configuration (such as a crimped state) and a radially-expanded configuration. The tissue anchors, including their respective terminal ends, may be situated closer to the longitudinal axis of the prosthetic valve when the tissue anchors are in the radially-contracted configuration compared to when the tissue anchors are in the radially-expanded configuration. In some embodiments, the tissue anchors may be configured to lie adjacent to, or flush with, a portion of the annular valve when the tissue anchors are in the radially-contracted configuration, and to deflect away from the annular valve when the tissue anchors are in the radially-expanded configuration. For example,
In some embodiments, the tissue anchors may have shape memory such that they are configured for self-expansion to the radially-expanded configuration. For example, the tissue anchors may be constructed of a shape memory material such as Nitinol and may be constructed to be biased towards the radially-expanded configuration. Additionally, or alternatively, the tissue anchors may be configured to expand to the radially-expanded configuration due to application of radially expansive forces thereupon.
In some embodiments, the at least one protective fabric covering may be arranged so as not to impede movement of the tissue anchors from the radially-contracted configuration to the radially-expanded configuration. That is, the tissue anchors may be configured to expand from the radially-contracted configuration to the radially-expanded configuration without interference from the at least one protective fabric covering. For example, the at least one protective fabric covering may be devoid of connections to the portions of the annular valve body which the tissue anchors deflect away from when the tissue anchors expand to the radially-expanded configuration. Thus, when the tissue anchors expand to the radially-expanded configuration, the at least one protective fabric covering may not create a connection between the tissue anchors and the valve body which would prevent tissue anchor expansion. Additionally, or alternatively, the at least one protective fabric covering may be sufficiently pliant so as to accommodate structural changes in the tissue anchor during radial expansion thereof.
In some embodiments, the at least one protective fabric covering may include a single strip of fabric wrapped about the connection point between the corresponding tissue anchor and the annular valve body. For example, the strip of fabric may be elongated between two opposite ends, and the strip may be wrapped about the at least one connection point such that one of the opposite ends is positioned over the other. For example,
In some embodiments, a terminal end of at least one tissue anchor may be configured to be situated in an atrial direction relative to the at least one protective fabric covering. In some embodiments, the terminal end of at least one tissue anchor may be configured to be situated in an atrial direction relative to the protective fabric covering associated with the tissue anchor. Additionally, or alternatively, the terminal end of at least one tissue anchor may be configured to be situated in an atrial direction relative to protective fabric coverings of at least one other tissue anchors. The terminal end of the at least one tissue anchor may be configured to be situated in an atrial direction relative to the protective fabric covering when the tissue anchor is in the radially-contracted configuration. Additionally, or alternatively, the terminal end of the at least one tissue anchor may be configured to be situated in an atrial direction relative to the protective fabric covering when the tissue anchor is in the radially-expanded configuration. For example,
As discussed above, the exemplary prosthetic valve may include a plurality of leaflets situated within the annular valve body in some embodiments.
In some embodiments, the leaflets may be connected to certain portions of the annular valve body. For example, the atrial ends of the leaflets may be connected to the annular valve body or to an intermediate structure (e.g., a liner) which may, in turn, be connected to the annular valve body. The leaflets may be connected to the annular valve body and/or to the intermediate structure by stitching, adhesive, staples, rivets, and/or any suitable fasteners. For example, in
In some embodiments, the exemplary tissue anchors of the prosthetic valve may be configured to engage ventricular tissue of a native heart valve, so as to anchor the prosthetic valve within the native heart valve. For example, the tissue anchors may be configured to contact the ventricular surface of the native heart valve, so as to prevent migration of the prosthetic valve in an atrial direction. Additionally, or alternatively, the tissue anchors may be configured to grasp or clamp tissue of the native heart valve to further anchor the prosthetic valve in place. For example,
In some embodiments, the exemplary prosthetic valve may additionally include a plurality of atrial tissue anchors. In some embodiments, the atrial tissue anchors may be configured to engage atrial tissue of the native mitral valve to anchor the prosthetic valve therein. In some embodiments, the atrial tissue anchors may be configured to be positioned at least partially within an atrium upon implantation of the prosthetic valve, and to engage atrial tissue of the native mitral valve. For example,
In some embodiments, the atrial tissue anchors may be configured to minimize or prevent migration of the prosthetic valve, including in a ventricular direction (that is, towards the ventricle), after the prosthetic valve is implanted. This may be due, at least in part, to the engagement of the atrial tissue anchors with native tissue (e.g., the atrial side of the native mitral valve) and the inability of the atrial tissue anchors to pass through the mitral valve orifice after the prosthetic valve is implanted. For example, the atrial tissue anchors may have sufficient length such that they may be configured to have a greater radius than the native mitral valve. Additionally, or alternatively, the atrial tissue anchors may be configured to grasp or clamp tissue of the native mitral valve to further anchor the prosthetic valve in place. For example, in the embodiment of
The prosthetic valve may include two atrial tissue anchors, three atrial tissue anchors, four atrial tissue anchors, five atrial tissue anchors, six atrial tissue anchors, seven atrial tissue anchors, eight atrial tissue anchors, nine atrial tissue anchors, ten atrial tissue anchors, eleven atrial tissue anchors, twelve atrial tissue anchors, thirteen atrial tissue anchors, fourteen atrial tissue anchors, fifteen atrial tissue anchors, sixteen atrial tissue anchors, seventeen atrial tissue anchors, eighteen atrial tissue anchors, nineteen atrial tissue anchors, twenty atrial tissue anchors, or any other suitable number of atrial tissue anchors. For example, exemplary prosthetic valve 6000 depicted in
In some embodiments, the annular valve body may include one or more frames. In some embodiments, the annular valve body may include an outer frame and an inner frame situated at least partially within the outer frame. In some embodiments, one or both of the inner frame and the outer frame may be annular, and the inner frame may be positioned within an opening of the outer frame. For example,
In some embodiments, the exemplary ventricular tissue anchors may be configured to extend from the annular outer frame. Additionally, or alternatively, the exemplary atrial tissue anchors may be configured to extend from the inner frame. For example,
In some embodiments, the at least one protective fabric covering may be positioned in a radially outer direction relative to the inner frame and annular outer frame. That is, the at least one protective fabric covering may be positioned exterior to both the inner frame and annular outer frame, and at a greater distance from the longitudinal axis of the prosthetic valve than are the inner frame and annular outer frame. In some embodiments, the entirety of the at least one protective fabric covering may be positioned in a radially outer direction relative to the inner frame and annular outer frame. Alternatively, a portion of the at least one protective fabric covering may be positioned in a radially outer direction relative to the inner frame and annular outer frame. This may be achieved, for example, because the at least one protective fabric covering may be arranged along an exterior surface of the annular outer frame, which may in turn be situated in a radially outer direction relative to the inner frame. Alternatively, the at least one protective fabric covering may be positioned on an element (e.g., a ventricular tissue anchor) which may extend radially outward from the inner frame and annular outer frame, thus positioning the at least one protective fabric covering in a radially outward direction from the inner frame and annular outer frame. For example, in
In some embodiments, the at least one protective fabric covering may be situated in a ventricular direction relative to the atrial tissue anchors. In some embodiments, the at least one protective fabric covering may be situated in a ventricular direction relative to some or all of the atrial tissue anchors. The at least one protective fabric covering may be situated in a ventricular direction relative to the atrial tissue anchors when the atrial tissue anchors are in a radially-contracted configuration. Additionally, or alternatively, the at least one protective fabric covering may be situated in a ventricular direction relative to the atrial tissue anchors when the atrial tissue anchors are in a radially-expanded configuration. For example,
In some embodiments, the atrial tissue anchors and ventricular tissue anchors may be angularly offset from each other, relative to the longitudinal axis of the prosthetic valve. That is, the atrial tissue anchors and ventricular tissue anchors may be situated at different positions about the circumference of the annular valve body. Because the at least one protective fabric covering may cover a portion of the ventricular tissue anchors, it follows that the at least one protective fabric covering is also angularly offset from the atrial tissue anchors. In some embodiments, the protective fabric coverings and atrial tissue anchors may be spaced at a regular interval about the circumference of the annular valve body. Alternatively, the protective fabric coverings and atrial tissue anchors may be spaced at another pattern about the circumference of the annular valve body. For example, in
The foregoing description has been presented for purposes of illustration. It is not exhaustive and is not limited to precise forms or embodiments disclosed. Modifications and adaptations of the embodiments will be apparent from consideration of the specification and practice of the disclosed embodiments. For example, while certain components have been described as being coupled to one another, such components may be integrated with one another or distributed in any suitable fashion.
Moreover, while illustrative embodiments have been described herein, the scope includes any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations based on the present disclosure. The elements in the claims are to be interpreted broadly based on the language employed in the claims and not limited to examples described in the present specification or during the prosecution of the application, which examples are to be construed as nonexclusive. Further, the steps of the disclosed methods can be modified in any manner, including reordering steps and/or inserting or deleting steps.
The features and advantages of the disclosure are apparent from the detailed specification, and thus, it is intended that the appended claims cover all systems and methods falling within the true spirit and scope of the disclosure. As used herein, the indefinite articles “a” and “an” mean “one or more.” Similarly, the use of a plural term does not necessarily denote a plurality unless it is unambiguous in the given context. Words such as “and” or “or” mean “and/or” unless specifically directed otherwise. Further, since numerous modifications and variations will readily occur from studying the present disclosure, it is not desired to limit the disclosure to the exact construction and operation illustrated and described, and, accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the disclosure.
Other embodiments will be apparent from consideration of the specification and practice of the embodiments disclosed herein. It is intended that the specification and examples be considered as example only, with a true scope and spirit of the disclosed embodiments being indicated by the following claims.
This application is a continuation of U.S. patent application Ser. No. 16/135,843, filed Sep. 19, 2018, now U.S. Pat. No. 10,799,345, which claims priority from U.S. Provisional Patent Application No. 62/560,384, filed Sep. 19, 2017, the content of each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4340091 | Skelton et al. | Jul 1982 | A |
4972494 | White et al. | Nov 1990 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5716417 | Girard et al. | Feb 1998 | A |
5741297 | Simon | Apr 1998 | A |
5776140 | Cottone | Jul 1998 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5961549 | Nguyen et al. | Oct 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6254609 | Vrba et al. | Jul 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6669724 | Park et al. | Dec 2003 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6755857 | Peterson et al. | Jun 2004 | B2 |
6926715 | Hauck et al. | Aug 2005 | B1 |
6939370 | Hartley et al. | Sep 2005 | B2 |
7074236 | Rabkin et al. | Jul 2006 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7261686 | Couvillon, Jr. | Aug 2007 | B2 |
7288097 | Séguin | Oct 2007 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7556632 | Zadno | Jul 2009 | B2 |
7563267 | Goldfarb et al. | Jul 2009 | B2 |
7563273 | Goldfarb et al. | Jul 2009 | B2 |
7608091 | Goldfarb et al. | Oct 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7655015 | Goldfarb et al. | Feb 2010 | B2 |
7736388 | Goldfarb et al. | Jun 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7811296 | Goldfarb et al. | Oct 2010 | B2 |
7837727 | Goetz et al. | Nov 2010 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
8052592 | Goldfarb et al. | Nov 2011 | B2 |
8057493 | Goldfarb et al. | Nov 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
D652927 | Braido et al. | Jan 2012 | S |
D653341 | Braido et al. | Jan 2012 | S |
8109996 | Stacchino et al. | Feb 2012 | B2 |
D660433 | Braido et al. | May 2012 | S |
D660967 | Braido et al. | May 2012 | S |
8216256 | Raschdorf, Jr. et al. | Jul 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8562672 | Bonhoeffer et al. | Oct 2013 | B2 |
8568475 | Nguyen et al. | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8657872 | Seguin | Feb 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8852272 | Gross et al. | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8870950 | Hacohen | Oct 2014 | B2 |
8945177 | Dell et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8986375 | Garde et al. | Mar 2015 | B2 |
8992604 | Gross et al. | Mar 2015 | B2 |
8998982 | Richter et al. | Apr 2015 | B2 |
9011468 | Ketai et al. | Apr 2015 | B2 |
9017399 | Gross et al. | Apr 2015 | B2 |
D730520 | Braido et al. | May 2015 | S |
D730521 | Braido et al. | May 2015 | S |
9023100 | Quadri et al. | May 2015 | B2 |
D732666 | Nguyen et al. | Jun 2015 | S |
9050188 | Schweich, Jr. et al. | Jun 2015 | B2 |
9060858 | Thornton et al. | Jun 2015 | B2 |
9072603 | Tuval et al. | Jul 2015 | B2 |
9095434 | Rowe | Aug 2015 | B2 |
9119719 | Zipory et al. | Sep 2015 | B2 |
9125740 | Morriss et al. | Sep 2015 | B2 |
9132009 | Hacohen et al. | Sep 2015 | B2 |
9173659 | Bodewadt et al. | Nov 2015 | B2 |
9180009 | Majkrzak et al. | Nov 2015 | B2 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9241790 | Lane et al. | Jan 2016 | B2 |
9241791 | Braido et al. | Jan 2016 | B2 |
9241792 | Benichou et al. | Jan 2016 | B2 |
9248014 | Lane et al. | Feb 2016 | B2 |
9277994 | Miller et al. | Mar 2016 | B2 |
9295551 | Straubinger et al. | Mar 2016 | B2 |
9295552 | McLean et al. | Mar 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
9320591 | Bolduc | Apr 2016 | B2 |
D755384 | Pesce et al. | May 2016 | S |
9345573 | Nyuli et al. | May 2016 | B2 |
9358107 | Nguyen et al. | Jun 2016 | B2 |
9387078 | Gross et al. | Jul 2016 | B2 |
9393110 | Levi et al. | Jul 2016 | B2 |
9439757 | Wallace et al. | Sep 2016 | B2 |
9445893 | Vaturi | Sep 2016 | B2 |
9463102 | Kelly | Oct 2016 | B2 |
9492273 | Wallace et al. | Nov 2016 | B2 |
9532870 | Cooper et al. | Jan 2017 | B2 |
9554897 | Lane et al. | Jan 2017 | B2 |
9554899 | Granada et al. | Jan 2017 | B2 |
9561103 | Granada et al. | Feb 2017 | B2 |
9566152 | Schweich, Jr. et al. | Feb 2017 | B2 |
9572665 | Lane et al. | Feb 2017 | B2 |
9597182 | Straubinger et al. | Mar 2017 | B2 |
9629716 | Seguin | Apr 2017 | B2 |
9662203 | Sheahan et al. | May 2017 | B2 |
9681952 | Hacohen et al. | Jun 2017 | B2 |
9717591 | Chau et al. | Aug 2017 | B2 |
9763657 | Hacohen et al. | Sep 2017 | B2 |
9770256 | Cohen et al. | Sep 2017 | B2 |
D800908 | Hariton et al. | Oct 2017 | S |
9788941 | Hacohen | Oct 2017 | B2 |
9895226 | Harari et al. | Feb 2018 | B1 |
9974651 | Hariton et al. | May 2018 | B2 |
10010414 | Cooper et al. | Jul 2018 | B2 |
10076415 | Metchik et al. | Sep 2018 | B1 |
10105222 | Metchik et al. | Oct 2018 | B1 |
10111751 | Metchik et al. | Oct 2018 | B1 |
10123873 | Metchik et al. | Nov 2018 | B1 |
10130475 | Metchik et al. | Nov 2018 | B1 |
10136993 | Metchik et al. | Nov 2018 | B1 |
10143552 | Wallace et al. | Dec 2018 | B2 |
10149761 | Granada et al. | Dec 2018 | B2 |
10154906 | Granada et al. | Dec 2018 | B2 |
10159570 | Metchik et al. | Dec 2018 | B1 |
10182908 | Tubishevitz et al. | Jan 2019 | B2 |
10226341 | Gross et al. | Mar 2019 | B2 |
10231837 | Metchik et al. | Mar 2019 | B1 |
10238493 | Metchik et al. | Mar 2019 | B1 |
10245143 | Gross et al. | Apr 2019 | B2 |
10245144 | Metchik et al. | Apr 2019 | B1 |
10292816 | Raanani et al. | May 2019 | B2 |
10299927 | McLean et al. | May 2019 | B2 |
10321995 | Christianson et al. | Jun 2019 | B1 |
10322020 | Lam et al. | Jun 2019 | B2 |
10327895 | Lozonschi et al. | Jun 2019 | B2 |
10335278 | McLean et al. | Jul 2019 | B2 |
10357360 | Hariton et al. | Jul 2019 | B2 |
10376361 | Gross et al. | Aug 2019 | B2 |
10390952 | Hariton et al. | Aug 2019 | B2 |
10426610 | Hariton et al. | Oct 2019 | B2 |
10463487 | Hariton et al. | Nov 2019 | B2 |
10463488 | Hariton et al. | Nov 2019 | B2 |
10507105 | Hariton et al. | Dec 2019 | B2 |
10507108 | Delgado et al. | Dec 2019 | B2 |
10507109 | Metchik et al. | Dec 2019 | B2 |
10512456 | Hacohen et al. | Dec 2019 | B2 |
10517719 | Miller et al. | Dec 2019 | B2 |
10524792 | Hernandez et al. | Jan 2020 | B2 |
10524903 | Hariton et al. | Jan 2020 | B2 |
10524910 | Hammer et al. | Jan 2020 | B2 |
10531872 | Hacohen et al. | Jan 2020 | B2 |
10548731 | Lashinski et al. | Feb 2020 | B2 |
10575948 | Iamberger et al. | Mar 2020 | B2 |
10595992 | Chambers | Mar 2020 | B2 |
10595997 | Metchik et al. | Mar 2020 | B2 |
10610358 | Vidlund et al. | Apr 2020 | B2 |
10631871 | Goldfarb et al. | Apr 2020 | B2 |
10646342 | Marr et al. | May 2020 | B1 |
10667908 | Hariton et al. | Jun 2020 | B2 |
10667912 | Dixon et al. | Jun 2020 | B2 |
10682227 | Hariton et al. | Jun 2020 | B2 |
10695177 | Hariton et al. | Jun 2020 | B2 |
10702385 | Hacohen | Jul 2020 | B2 |
10722360 | Hariton et al. | Jul 2020 | B2 |
10758342 | Chau et al. | Sep 2020 | B2 |
10758344 | Hariton et al. | Sep 2020 | B2 |
10799345 | Hariton et al. | Oct 2020 | B2 |
10813760 | Metchik et al. | Oct 2020 | B2 |
10820998 | Marr et al. | Nov 2020 | B2 |
10842627 | Delgado et al. | Nov 2020 | B2 |
10849748 | Hariton et al. | Dec 2020 | B2 |
10856972 | Hariton et al. | Dec 2020 | B2 |
10856975 | Hariton et al. | Dec 2020 | B2 |
10856978 | Straubinger et al. | Dec 2020 | B2 |
10864078 | Hariton et al. | Dec 2020 | B2 |
10874514 | Dixon et al. | Dec 2020 | B2 |
10881511 | Hariton et al. | Jan 2021 | B2 |
10888422 | Hariton et al. | Jan 2021 | B2 |
10888425 | Delgado et al. | Jan 2021 | B2 |
10888644 | Ratz et al. | Jan 2021 | B2 |
10905548 | Hariton et al. | Feb 2021 | B2 |
10905549 | Hariton et al. | Feb 2021 | B2 |
10905552 | Dixon et al. | Feb 2021 | B2 |
10905554 | Cao | Feb 2021 | B2 |
10918483 | Metchik et al. | Feb 2021 | B2 |
10925595 | Hacohen et al. | Feb 2021 | B2 |
10925732 | Delgado et al. | Feb 2021 | B2 |
10945843 | Delgado et al. | Mar 2021 | B2 |
10945844 | McCann et al. | Mar 2021 | B2 |
10959846 | Marr et al. | Mar 2021 | B2 |
10973636 | Hariton et al. | Apr 2021 | B2 |
10993809 | McCann et al. | May 2021 | B2 |
11065114 | Raanani et al. | Jul 2021 | B2 |
11083582 | McCann et al. | Aug 2021 | B2 |
11147672 | McCann et al. | Oct 2021 | B2 |
11179240 | Delgado et al. | Nov 2021 | B2 |
11291545 | Hacohen | Apr 2022 | B2 |
11291546 | Gross et al. | Apr 2022 | B2 |
11291547 | Gross et al. | Apr 2022 | B2 |
11304806 | Hariton et al. | Apr 2022 | B2 |
11389297 | Franklin et al. | Jul 2022 | B2 |
20010005787 | Oz et al. | Jun 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20020013571 | Goldfarb et al. | Jan 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030074059 | Nguyen et al. | Apr 2003 | A1 |
20040030382 | St. Goar et al. | Feb 2004 | A1 |
20040186558 | Pavcnik et al. | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040236354 | Seguin | Nov 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050080474 | Andreas et al. | Apr 2005 | A1 |
20050085900 | Case et al. | Apr 2005 | A1 |
20050137681 | Shoemaker et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137699 | Salahieh et al. | Jun 2005 | A1 |
20050203618 | Sharkawy et al. | Sep 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050256566 | Gabbay | Nov 2005 | A1 |
20060004469 | Sokel | Jan 2006 | A1 |
20060020275 | Goldfarb et al. | Jan 2006 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060030863 | Fields et al. | Feb 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060184203 | Martin et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060216404 | Seyler et al. | Sep 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070038293 | St. Goar et al. | Feb 2007 | A1 |
20070056346 | Spenser et al. | Mar 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070197858 | Goldfarb et al. | Aug 2007 | A1 |
20070198077 | Cully et al. | Aug 2007 | A1 |
20070213810 | Newhauser et al. | Sep 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070219630 | Chu | Sep 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080065204 | Macoviak et al. | Mar 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090082844 | Zacharias et al. | Mar 2009 | A1 |
20090105794 | Ziarno et al. | Apr 2009 | A1 |
20090125098 | Chuter | May 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090163934 | Raschdorf, Jr. et al. | Jun 2009 | A1 |
20090259306 | Rowe | Oct 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20100022823 | Goldfarb et al. | Jan 2010 | A1 |
20100023120 | Holecek et al. | Jan 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100161036 | Pintor et al. | Jun 2010 | A1 |
20100185277 | Braido et al. | Jul 2010 | A1 |
20100256737 | Pollock et al. | Oct 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20100324595 | Linder et al. | Dec 2010 | A1 |
20100331971 | Keranen et al. | Dec 2010 | A1 |
20110004227 | Goldfarb et al. | Jan 2011 | A1 |
20110004299 | Navia et al. | Jan 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110066233 | Thornton et al. | Mar 2011 | A1 |
20110082538 | Dahlgren et al. | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110144742 | Madrid et al. | Jun 2011 | A1 |
20110208283 | Rust | Aug 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110245911 | Quill et al. | Oct 2011 | A1 |
20110251683 | Tabor | Oct 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110282439 | Thill et al. | Nov 2011 | A1 |
20110306916 | Nitzan et al. | Dec 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120016468 | Robin et al. | Jan 2012 | A1 |
20120022629 | Perera et al. | Jan 2012 | A1 |
20120022633 | Olson et al. | Jan 2012 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120059458 | Buchbinder | Mar 2012 | A1 |
20120065464 | Ellis et al. | Mar 2012 | A1 |
20120078237 | Wang et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120089223 | Nguyen et al. | Apr 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120165930 | Gifford, III et al. | Jun 2012 | A1 |
20120277845 | Bowe | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120300063 | Majkrzak et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130030519 | Tran et al. | Jan 2013 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130066341 | Ketai et al. | Mar 2013 | A1 |
20130066342 | Dell et al. | Mar 2013 | A1 |
20130144381 | Quadri et al. | Jun 2013 | A1 |
20130178930 | Straubinger et al. | Jul 2013 | A1 |
20130190861 | Chau et al. | Jul 2013 | A1 |
20130231735 | Deem et al. | Sep 2013 | A1 |
20130253643 | Rolando et al. | Sep 2013 | A1 |
20130261738 | Clague et al. | Oct 2013 | A1 |
20130274870 | Lombardi et al. | Oct 2013 | A1 |
20130282059 | Ketai et al. | Oct 2013 | A1 |
20130289711 | Liddy et al. | Oct 2013 | A1 |
20130289740 | Liddy et al. | Oct 2013 | A1 |
20130304200 | McLean et al. | Nov 2013 | A1 |
20140000112 | Braido et al. | Jan 2014 | A1 |
20140018915 | Biadillah et al. | Jan 2014 | A1 |
20140067050 | Costello et al. | Mar 2014 | A1 |
20140142688 | Duffy et al. | May 2014 | A1 |
20140172077 | Bruchman et al. | Jun 2014 | A1 |
20140172082 | Bruchman et al. | Jun 2014 | A1 |
20140194970 | Chobotov | Jul 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140207231 | Hacohen et al. | Jul 2014 | A1 |
20140214157 | Börtlein et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140222142 | Kovalsky et al. | Aug 2014 | A1 |
20140236287 | Clague et al. | Aug 2014 | A1 |
20140236289 | Alkhatib | Aug 2014 | A1 |
20140249622 | Carmi et al. | Sep 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140277409 | Bortlein et al. | Sep 2014 | A1 |
20140277411 | Bortlein et al. | Sep 2014 | A1 |
20140277412 | Börtlein et al. | Sep 2014 | A1 |
20140277418 | Miller | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296969 | Tegels et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140331475 | Duffy et al. | Nov 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140358222 | Gorman, III et al. | Dec 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140379074 | Spence et al. | Dec 2014 | A1 |
20150018944 | O'Connell et al. | Jan 2015 | A1 |
20150032205 | Matheny | Jan 2015 | A1 |
20150142100 | Morriss et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150157457 | Hacohen | Jun 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150173896 | Richter et al. | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150196390 | Ma et al. | Jul 2015 | A1 |
20150196393 | Vidlund et al. | Jul 2015 | A1 |
20150216661 | Hacohen et al. | Aug 2015 | A1 |
20150238313 | Spence et al. | Aug 2015 | A1 |
20150245934 | Lombardi et al. | Sep 2015 | A1 |
20150250588 | Yang et al. | Sep 2015 | A1 |
20150272730 | Melnick et al. | Oct 2015 | A1 |
20150272731 | Racchini et al. | Oct 2015 | A1 |
20150272734 | Sheps et al. | Oct 2015 | A1 |
20150305903 | Kitaoka | Oct 2015 | A1 |
20150320556 | Levi et al. | Nov 2015 | A1 |
20150327994 | Morriss et al. | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150335429 | Morriss et al. | Nov 2015 | A1 |
20150351903 | Morriss et al. | Dec 2015 | A1 |
20150351904 | Cooper et al. | Dec 2015 | A1 |
20150351906 | Hammer et al. | Dec 2015 | A1 |
20150359629 | Ganesan et al. | Dec 2015 | A1 |
20150359631 | Sheahan et al. | Dec 2015 | A1 |
20160030169 | Shahriari | Feb 2016 | A1 |
20160030171 | Quijano et al. | Feb 2016 | A1 |
20160089482 | Siegenthaler | Mar 2016 | A1 |
20160095700 | Righini | Apr 2016 | A1 |
20160100939 | Armstrong et al. | Apr 2016 | A1 |
20160113765 | Ganesan et al. | Apr 2016 | A1 |
20160113766 | Ganesan et al. | Apr 2016 | A1 |
20160113768 | Ganesan et al. | Apr 2016 | A1 |
20160158497 | Tran et al. | Jun 2016 | A1 |
20160175095 | Dienno et al. | Jun 2016 | A1 |
20160184098 | Vaturi | Jun 2016 | A1 |
20160220367 | Barrett | Aug 2016 | A1 |
20160262885 | Sandstrom et al. | Sep 2016 | A1 |
20160270911 | Ganesan et al. | Sep 2016 | A1 |
20160310268 | Oba | Oct 2016 | A1 |
20160317305 | Pelled et al. | Nov 2016 | A1 |
20160324633 | Gross et al. | Nov 2016 | A1 |
20160324635 | Vidlund et al. | Nov 2016 | A1 |
20160331525 | Straubinger et al. | Nov 2016 | A1 |
20160331526 | Schweich, Jr. et al. | Nov 2016 | A1 |
20160338706 | Rowe | Nov 2016 | A1 |
20160374801 | Jimenez et al. | Dec 2016 | A1 |
20160374802 | Levi et al. | Dec 2016 | A1 |
20170042678 | Ganesan et al. | Feb 2017 | A1 |
20170049435 | Sauer et al. | Feb 2017 | A1 |
20170056166 | Ratz et al. | Mar 2017 | A1 |
20170056171 | Cooper et al. | Mar 2017 | A1 |
20170065411 | Grundeman et al. | Mar 2017 | A1 |
20170100236 | Robertson et al. | Apr 2017 | A1 |
20170128205 | Tamir et al. | May 2017 | A1 |
20170135816 | Lashinski et al. | May 2017 | A1 |
20170189174 | Braido et al. | Jul 2017 | A1 |
20170209264 | Chau et al. | Jul 2017 | A1 |
20170224323 | Rowe et al. | Aug 2017 | A1 |
20170231757 | Gassler | Aug 2017 | A1 |
20170231759 | Geist et al. | Aug 2017 | A1 |
20170231766 | Hariton et al. | Aug 2017 | A1 |
20170239048 | Goldfarb et al. | Aug 2017 | A1 |
20170325948 | Wallace et al. | Nov 2017 | A1 |
20170333183 | Backus | Nov 2017 | A1 |
20170333187 | Hariton et al. | Nov 2017 | A1 |
20170367823 | Hariton et al. | Dec 2017 | A1 |
20180000580 | Wallace et al. | Jan 2018 | A1 |
20180014930 | Hariton et al. | Jan 2018 | A1 |
20180021129 | Peterson et al. | Jan 2018 | A1 |
20180028215 | Cohen | Feb 2018 | A1 |
20180049873 | Manash et al. | Feb 2018 | A1 |
20180055630 | Patel et al. | Mar 2018 | A1 |
20180098850 | Rafiee et al. | Apr 2018 | A1 |
20180116790 | Ratz et al. | May 2018 | A1 |
20180116843 | Schreck et al. | May 2018 | A1 |
20180125644 | Conklin | May 2018 | A1 |
20180132999 | Perouse | May 2018 | A1 |
20180153689 | Maimon et al. | Jun 2018 | A1 |
20180161159 | Lee et al. | Jun 2018 | A1 |
20180206983 | Noe et al. | Jul 2018 | A1 |
20180214263 | Rolando et al. | Aug 2018 | A1 |
20180243086 | Barbarino et al. | Aug 2018 | A1 |
20180250126 | O'Connor et al. | Sep 2018 | A1 |
20180250130 | Hariton et al. | Sep 2018 | A1 |
20180250147 | Syed | Sep 2018 | A1 |
20180256323 | Hariton et al. | Sep 2018 | A1 |
20180256325 | Hariton et al. | Sep 2018 | A1 |
20180271654 | Hariton et al. | Sep 2018 | A1 |
20180271655 | Hariton et al. | Sep 2018 | A1 |
20180289479 | Hariton et al. | Oct 2018 | A1 |
20180296333 | Dixon et al. | Oct 2018 | A1 |
20180296336 | Cooper et al. | Oct 2018 | A1 |
20180325671 | Abunassar et al. | Nov 2018 | A1 |
20180338829 | Hariton et al. | Nov 2018 | A1 |
20180338830 | Hariton et al. | Nov 2018 | A1 |
20180338831 | Hariton et al. | Nov 2018 | A1 |
20180344457 | Gross et al. | Dec 2018 | A1 |
20180344490 | Fox et al. | Dec 2018 | A1 |
20180353294 | Calomeni et al. | Dec 2018 | A1 |
20180360457 | Ellis et al. | Dec 2018 | A1 |
20190000613 | Delgado et al. | Jan 2019 | A1 |
20190015093 | Hacohen et al. | Jan 2019 | A1 |
20190015200 | Delgado et al. | Jan 2019 | A1 |
20190021852 | Delgado et al. | Jan 2019 | A1 |
20190053896 | Adamek-Bowers et al. | Feb 2019 | A1 |
20190060060 | Chau et al. | Feb 2019 | A1 |
20190060068 | Cope et al. | Feb 2019 | A1 |
20190060070 | Groothuis et al. | Feb 2019 | A1 |
20190069997 | Ratz et al. | Mar 2019 | A1 |
20190083242 | Hariton et al. | Mar 2019 | A1 |
20190083243 | Hariton et al. | Mar 2019 | A1 |
20190083246 | Hariton et al. | Mar 2019 | A1 |
20190083247 | Hariton et al. | Mar 2019 | A1 |
20190083261 | Perszyk et al. | Mar 2019 | A1 |
20190105153 | Barash et al. | Apr 2019 | A1 |
20190117391 | Humair | Apr 2019 | A1 |
20190175339 | Vidlund | Jun 2019 | A1 |
20190175342 | Hariton | Jun 2019 | A1 |
20190183639 | Moore | Jun 2019 | A1 |
20190192295 | Spence et al. | Jun 2019 | A1 |
20190328519 | Hariton et al. | Oct 2019 | A1 |
20190336280 | Naor et al. | Nov 2019 | A1 |
20190343627 | Hariton et al. | Nov 2019 | A1 |
20190350701 | Adamek-Bowers et al. | Nov 2019 | A1 |
20190365530 | Hoang et al. | Dec 2019 | A1 |
20190388218 | Vidlund et al. | Dec 2019 | A1 |
20190388220 | Vidlund et al. | Dec 2019 | A1 |
20190388223 | Hariton et al. | Dec 2019 | A1 |
20200000449 | Goldfarb et al. | Jan 2020 | A1 |
20200000579 | Manash et al. | Jan 2020 | A1 |
20200015964 | Noe et al. | Jan 2020 | A1 |
20200030098 | Delgado et al. | Jan 2020 | A1 |
20200046497 | Hariton et al. | Feb 2020 | A1 |
20200054335 | Hernandez et al. | Feb 2020 | A1 |
20200054451 | Hariton et al. | Feb 2020 | A1 |
20200060818 | Geist et al. | Feb 2020 | A1 |
20200069424 | Hariton et al. | Mar 2020 | A1 |
20200113677 | McCann et al. | Apr 2020 | A1 |
20200113689 | McCann et al. | Apr 2020 | A1 |
20200113692 | McCann et al. | Apr 2020 | A1 |
20200129294 | Hariton et al. | Apr 2020 | A1 |
20200138567 | Marr et al. | May 2020 | A1 |
20200146671 | Hacohen et al. | May 2020 | A1 |
20200163761 | Hariton et al. | May 2020 | A1 |
20200214832 | Metchik et al. | Jul 2020 | A1 |
20200237512 | McCann et al. | Jul 2020 | A1 |
20200246136 | Marr et al. | Aug 2020 | A1 |
20200246140 | Hariton et al. | Aug 2020 | A1 |
20200253600 | Darabian | Aug 2020 | A1 |
20200261094 | Goldfarb et al. | Aug 2020 | A1 |
20200315786 | Metchik et al. | Oct 2020 | A1 |
20200337842 | Metchik et al. | Oct 2020 | A1 |
20210085455 | Bateman et al. | Mar 2021 | A1 |
20210093449 | Hariton et al. | Apr 2021 | A1 |
20210106419 | Abunassar | Apr 2021 | A1 |
20210113331 | Quadri et al. | Apr 2021 | A1 |
20210137680 | Kizuka et al. | May 2021 | A1 |
20210259835 | Tyler, II et al. | Aug 2021 | A1 |
20220000612 | Hacohen | Jan 2022 | A1 |
Number | Date | Country |
---|---|---|
2822801 | Aug 2006 | CA |
103974674 | Aug 2014 | CN |
1264582 | Dec 2002 | EP |
1637092 | Mar 2006 | EP |
2 446 915 | May 2012 | EP |
2349124 | Oct 2018 | EP |
3583922 | Dec 2019 | EP |
3270825 | Apr 2020 | EP |
2485795 | Sep 2020 | EP |
WO 2003020179 | Mar 2003 | WO |
WO 2004028399 | Apr 2004 | WO |
WO 2006007389 | Jan 2006 | WO |
WO 2006086434 | Aug 2006 | WO |
WO 2006116558 | Nov 2006 | WO |
WO 2006128193 | Nov 2006 | WO |
WO 2007047488 | Apr 2007 | WO |
WO 2008029296 | Mar 2008 | WO |
WO 2009091509 | Jul 2009 | WO |
WO 2010006627 | Jan 2010 | WO |
WO 2010027485 | Mar 2010 | WO |
WO 2010045297 | Apr 2010 | WO |
WO 2010057262 | May 2010 | WO |
WO 2011069048 | Jun 2011 | WO |
WO 2011144351 | Nov 2011 | WO |
WO 2012011108 | Jan 2012 | WO |
WO 2012036740 | Mar 2012 | WO |
WO 2012048035 | Apr 2012 | WO |
WO 2013059747 | Apr 2013 | WO |
WO 2013072496 | May 2013 | WO |
WO 2013078497 | Jun 2013 | WO |
WO 2013114214 | Aug 2013 | WO |
WO 2013175468 | Nov 2013 | WO |
WO 2014115149 | Jul 2014 | WO |
2014121280 | Aug 2014 | WO |
WO 2014144937 | Sep 2014 | WO |
WO 2014164364 | Oct 2014 | WO |
WO 2016016899 | Feb 2016 | WO |
WO 2016098104 | Jun 2016 | WO |
WO 2016125160 | Aug 2016 | WO |
WO 2016150806 | Sep 2016 | WO |
WO 2018025260 | Feb 2018 | WO |
WO 2018025263 | Feb 2018 | WO |
WO 2018029680 | Feb 2018 | WO |
WO 2018039631 | Mar 2018 | WO |
WO 2018112429 | Jun 2018 | WO |
WO 2018118717 | Jun 2018 | WO |
WO 2018131042 | Jul 2018 | WO |
WO 2018131043 | Jul 2018 | WO |
WO 2019027507 | Feb 2019 | WO |
WO 2019195860 | Oct 2019 | WO |
WO 2020167677 | Aug 2020 | WO |
2021156866 | Aug 2021 | WO |
2021186424 | Sep 2021 | WO |
Entry |
---|
International Search Report mailed on Dec. 5, 2011, by the United States Patent and Trademark Office in PCT/IL2011/000582 (3 pages). |
International Search Report mailed on Mar. 27, 2018, by the European Patent Office in PCT/IL2017/050849 (5 pages). |
International Search Report mailed on May 30, 2016, by the European Patent Office in PCT/IL2016/050125 (6 pages). |
International Search Report mailed on Nov. 24, 2017, by the European Patent Office in PCT/IL2017/050873 (5 pages). |
International Search Report mailed on Oct. 27, 2015, by the European Patent Office in PCT/IL2015/050792 (3 pages). |
International Search Report mailed on Sep. 4, 2014, by the European Patent Office in PCT/IL2014/050087 (6 pages). |
Written Opinion of the International Searching Authority issued by the United States Patent and Trademark Office in PCT/IL2011/000582 (12 pages). |
Written Opinion of the International Searching Authority issued by the European Patent Office in PCT/IL2017/050849 (10 pages). |
Written Opinion of the International Searching Authority issued by the European Patent Office in PCT/IL2016/050125 (7 pages). |
Written Opinion of the International Searching Authority issued by the European Patent Office in PCT/IL2014/050087 (10 pages). |
Written Opinion of the International Searching Authority issued by the European Patent Office in PCT/IL2015/050792 (5 pages). |
Written Opinion of the International Searching Authority issued by the European Patent Office in PCT/IL2017/050873 (12 pages). |
An Office Action dated Jan. 26, 2022, which issued during the prosecution of U.S. Appl. No. 16/888,210. |
Notice of Allowance dated Jan. 31, 2022, which issued during the prosecution of U.S. Appl. No. 17/479,418. |
An Office Action dated Mar. 18, 2022, which issued during the prosecution of U.S. Appl. No. 16/746,489. |
Notice of Allowance dated Mar. 22, 2022, which issued during the prosecution of U.S. Appl. No. 17/366,711. |
Notice of Allowance dated Mar. 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/768,909. |
An Office Action dated Dec. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,969. |
An Office Action dated Jan. 24, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466. |
An Office Action dated Apr. 11, 2022, which issued during the prosecution of U.S. Appl. No. 17/473,472. |
IPR2021-00383 Preliminary Guidance dated Jan. 31, 2022. |
An International Search Report and a Written Opinion both dated May 3, 2022, which issued during the prosecution of Applicant's PCT/IL2021/051433. |
An Office Action dated Jul. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/144,054. |
An Office Action dated Jun. 28, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,969. |
An Office Action together with an English Summary dated May 7, 2022 which issued during the prosecution of Chinese Patent Application No. 201880058940.2. |
Ex Parte Quayle dated May 2, 2022, which issued during the prosecution of U.S. Appl. No. 16/879,952. |
IPR2021-00383 Final Written Decision dated Jul. 18, 2022. |
IPR2021-01051 Preliminary Guidance Patent Owner's Motion to Amend dated Jun. 24, 2022. |
Notice of Allowance dated May 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/680,739. |
Sündermann, Simon H. et al., Feasibility of the Engager™ aortic transcatheter valve system using a flexible over-the-wire design, 42 European Journal of Cardio-Thoracic Surgery, Jun. 27, 2012, at e48 (5 pages). |
Symetis S.A., Clinical Investigation Plan for Acurate Neo™ TA Delivery System, Protocol 2015-01, ver. 2, ClinicalTrials.gov Identifier NCT02950428, Sep. 8, 2015 (76 pages). |
Tchetche, Didier et al., New-generation TAVI devices: description and specifications, 10 EuroIntervention (Supplement), Sep. 2014, at U90 (11 pages). |
Batista, Randas J. V. et al., Partial Left Ventriculectomy to Treat End-Stage Heart Disease, 64 Annals Thoracic Surgery 634-38 (1997) (5 pages). |
Beall, Jr., Arthur C. et al., Clinical Experience with a Dacron Velour-Covered Teflon-Disc Mitral-Valve Prosthesis, 5 Annals Thoracic Surgery 402-10 (1968) (9 pages). |
Fucci, Carlo et al., Improved Results with Mitral Valve Repair Using New Surgical Techniques, 9 Eur. J. Cardiothoracic Surgery 621-27 (1995) (7 pages). |
Maisano, Francesco et al., The Edge-To-Edge Technique: A Simplified Method to Correct Mitral Insufficiency, 13 Eur. J. Cardiothoracic Surgery 240-46 (1998) (7 pages). |
Stone, Gregg W. et al., Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles, 66 J. Am. C. Cardiology 278-307 (2015) (30 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Paper 10: Decision Granting Institution of Inter Partes Review (Dec. 10, 2021) (42 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Petitioners' Opposition to Patent Owner's Contingent Motion to Amend (Jan. 5, 2022) (32 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Petitioners' Reply to Patent Owner's Response (Jan. 5, 2022) (41 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Exhibit 2009: Percutaneous Mitral Leaflet Repair: MitraClip Therapy for Mitral Regurgitation (Aug. 17, 2012) (8 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Exhibit 2010: Deposition of Dr. Ivan Vesely, Ph.D. (Sep. 27, 2021) (170 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Exhibit 2014: Second Declaration of Dr. Michael Sacks (Oct. 13, 2021) (28 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Patent Owner's Contingent Motion to Amend Under 37 C.F.R. § 42.121 (Oct. 13, 2021) (35 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Patent Owner's Response Pursuant to 37 C.F.R. § 42.120 (Oct. 13, 2021) (75 pages). |
Fann, James I. et al., Beating Heart Catheter-Based Edge-to-Edge Mitral Valve Procedure in a Porcine Model: Efficacy and Healing Response, 110 Circulation, Aug. 2004, at 988 (6 pages). |
Feldman, Ted et al., Percutaneous Mitral Repair With the MitraClip System: Safety and Midterm Durability in the Initial EVEREST Cohort, 54 J. Am. Coll. Cardiology, Aug. 2009, at 686 (9 pages). |
Feldman, Ted et al., Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique: Six-Month Results of the EVEREST Phase I Clinical Trial, 46 J. Am. Coll. Cardiology, Dec. 2005, at 3134 (7 pages). |
Maisano, Francesco et al., The Evolution From Surgery to Percutaneous Mitral Valve Interventions: The Role of the Edge-to-Edge Technique, 58 J. Am. Coll. Cardiology, Nov. 2011, at 2174 (9 pages). |
An Office Action dated Jul. 27, 2022, which issued during the prosecution of U.S. Appl. No. 16/881,350. |
An Office Action dated Sep. 21, 2022, which issued during the prosecution of U.S. Appl. No. 16/776,581. |
An Office Action dated Jul. 20, 2022, which issued during the prosecution of U.S. Appl. No. 17/101,787. |
An Office Action dated Sep. 16, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466. |
An Office Action dated Aug. 1, 2022, which issued during the prosecution of European Patent Application No. 18826823.9. |
European Search Report dated Sep. 6, 2022 which issued during the prosecution of Applicant's European App No. 22161862.2. |
IPR2021-01051 Petitioners' Reply to Preliminary Guidance dated Aug. 2, 2022. |
IPR2021-01051 Patent Owner's Sur-Reply to Petitioners' Reply to Preliminary Guidance dated Aug. 23, 2022. |
An Office Action dated Aug. 5, 2022, which issued during the prosecution of U.S. Appl. No. 16/760,147. |
An Office Action dated Sep. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/896,858. |
Ando, Tomo et al., Iatrogenic Ventricular Septal Defect Following Transcatheter Aortic Valve Replacement: A Systematic Review, 25 Heart, Lung, and Circulation 968-74 (Apr. 22, 2016) (7 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Exhibit 1014: Transcript of proceedings held May 20, 2021 (May 26, 2021) (21 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Exhibit 1015: Facilitate, Merriam-Webster.com, https://www. www.merriam-webster.com/dictionary/facilitate (accessed May 27, 2021) (5 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Paper 12: Petitioners' Authorized Reply to Patent Owner's Preliminary Response (May 27, 2021) (9 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Paper 13: Patent Owner's Authorized Surreply to Petitioner's Reply to Patent Owner's Preliminary Response (Jun. 4, 2021) (8 pages). |
Edwards Lifesciences Corp. v. Cardiovalve Ltd., IPR2021-00383, Paper 16: Institution Decision (Jul. 20, 2021) (51 pages). |
Poirier, Nancy et al., A Novel Repair for Patients with Atrioventricular Septal Defect Requiring Reoperation for Left Atrioventricular Valve Regurgitation, 18 Eur. J. Cardiothoracic Surgery 54-61 (2000) (8 pages). |
Urena, Marina et al., Transseptal Transcatheter Mitral Valve Replacement Using Balloon-Expandable Transcatheter Heart Valves, JACC: Cardiovascular Interventions 1905-19 (2017) (15 pages). |
An Office Action dated Nov. 2, 2022, which issued during the prosecution of U.S. Appl. No. 17/004,693. |
An Office Action dated Nov. 28, 2022, which issued during the prosecution of U.S. Appl. No. 17/141,853. |
An Office Action dated Oct. 19, 2022, which issued during the prosecution of U.S. Appl. No. 17/875,589. |
An Office Action dated Oct. 26, 2022, which issued during the prosecution of U.S. Appl. No. 16/746,489. |
An Office Action dated Mar. 3, 2023, which issued during the prosecution of European Patent Application No. 17 751 143.3. |
An Office Action dated Mar. 20, 2023, which issued during the prosecution of U.S. Appl. No. 17/181,722. |
Number | Date | Country | |
---|---|---|---|
20200397573 A1 | Dec 2020 | US |
Number | Date | Country | |
---|---|---|---|
62560384 | Sep 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16135843 | Sep 2018 | US |
Child | 17010886 | US |